Glenmede Trust’s Adaptimmune Therapeutics ADAP Stock Holding History

Glenmede Trust’s Portfolio ADAP Stock Details ADAP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q4	–	Sell	-375	Closed	–	–	3000
2019 Q3	$0	Hold	375	–	–	﹤0.01%	2999
2019 Q2	$1	Hold	375	–	–	﹤0.01%	2934
2019 Q1	$1	Buy	+375	New	+$1.75K	﹤0.01%	2905
2018 Q4	–	Sell	-8,823	Closed	-$119K	–	3007
2018 Q3	$119K	Hold	8,823	–	–	﹤0.01%	1270
2018 Q2	$105K	Hold	8,823	–	–	﹤0.01%	1247
2018 Q1	$58K	Hold	8,823	–	–	﹤0.01%	1571
2017 Q4	$58K	Hold	8,823	–	–	﹤0.01%	1571
2017 Q3	$72K	Hold	8,823	–	–	﹤0.01%	1510
2017 Q2	$48K	Hold	8,823	–	–	﹤0.01%	1610
2017 Q1	$48K	Hold	8,823	–	–	﹤0.01%	1610
2016 Q4	$35K	Sell	8,823 -1,175	-12%	-$5.64K	﹤0.01%	1713
2016 Q3	$70K	Sell	9,998 -10,925	-52%	-$83.3K	﹤0.01%	1489
2016 Q2	$170K	Buy	20,923 +17,823	+575%	+$168K	﹤0.01%	1219
2016 Q1	$25K	Hold	3,100	–	–	﹤0.01%	1739
2015 Q4	$37K	Buy	3,100 +600	+24%	+$5.88K	﹤0.01%	1659
2015 Q3	$29K	Buy	2,500 +675	+37%	+$9.54K	﹤0.01%	1770
2015 Q2	$33K	Buy	+1,825	New	+$31.3K	﹤0.01%	1753

Other funds holding ADAP

MCMC

Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Man Group London, United Kingdom $55.1B AUM 24.23% 1-Year Est. Return

TAM

TFG Asset Management Grand Cayman, Cayman Islands $515M AUM 24.47% 1-Year Est. Return

RSCM

Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

Glenmede Trust's ADAP Position: Q4 2019 in Review

Glenmede Trust sold out of Adaptimmune Therapeutics (ADAP) in Q4 2019, closing a stake of 375 shares.

Glenmede Trust first reported a position in ADAP in Q2 2015 and held it in 17 quarters. The position peaked at $170K in Q2 2016. 43 funds tracked by Wall St. Rank hold ADAP as of Q4 2019.

Glenmede Trust reported no remaining Adaptimmune Therapeutics position as of Q4 2019 after selling out during the quarter.
Glenmede Trust sold 375 Adaptimmune Therapeutics shares in Q4 2019.
Glenmede Trust first reported a position in Adaptimmune Therapeutics in Q2 2015 and held it in 17 quarters.
Glenmede Trust's Adaptimmune Therapeutics position peaked at $170K in Q2 2016.
43 funds tracked by Wall St. Rank held Adaptimmune Therapeutics as of Q4 2019.

Based on Glenmede Trust's 13F filing for Q4 2019, filed 12 Feb 2020.